Analysts Chase Natera Higher as Options Caution Fades

Bulls argue that Natera holds over 90% share in a $15 billion MRD market through Signatera, with reimbursement advantages that create a durable moat. Clinical volume grew roughly 60% in 2025, Medicare coverage has expanded, and the average selling price of $1,275 remains well below the $3,590 Medicare rate, suggesting further room on both revenue and margin. Management has pointed to eight-to-nine-figure pharma data licensing deals and around $70 million of revenue from that channel in 2026, while the long-term EBIT margin target of 25%-plus gives the growth story a profitability destination. Bears push back that MRD adoption in mature indications like colorectal cancer adjuvant may already exceed 50%, that competitive pressure is building across both oncology and women's health, and that faster adoption of the Ultra Signatera product could outpace COGS declines in the near term, squeezing gross margins. The colorectal screening data the market wants won't arrive until mid-2027, with commercial launch not before 2028 to 2029.

Positioning tells a different story from the analyst noise. Short interest is modest, at 3.5% of the float, and has drifted slightly lower over the past week. Borrow is cheap at 0.38%, and availability is extremely loose with roughly 8,000% of short interest available to lend, meaning there is abundant supply for anyone wanting to add to a short position and no sign of squeeze pressure anywhere in the lending market. What has been moving is the options market, but in the opposite direction from what you might expect given Tuesday's selloff. The put/call ratio has collapsed to 1.05 from 1.65 in mid-September, nearly 1.4 standard deviations below the 20-day mean of 1.34. A month ago, options traders were running near the most defensive posture of the past year. Now they are comparatively relaxed, with demand for downside protection fading even as the stock pulls back. That divergence is worth watching.

Insider activity is wholly benign in character but worth noting for context. The CEO, Solomon Moshkevich as President of Clinical Diagnostics, and director Jonathan Sheena all sold shares in late September and early October. The combined 90-day net is around 198,600 shares sold at a net value of $68 million. Every transaction was executed under a pre-arranged 10b5-1 plan, making these scheduled sales rather than discretionary signals. The ownership register shows BlackRock at 7.6% of shares, JPMorgan Asset Management at 7.2%, and T. Rowe Price at 7.0%, all of which added modestly in the most recent reporting period. No Schedule 13D activist is on the register.

The previous earnings print, delivered in August, produced a 17% single-day gain and held roughly 13% of that into the following five days, a reminder that Natera has rewarded bulls on recent results. With 30 days to the next report and retail attention running about 1.3 standard deviations above its 90-day norm on Wikipedia views, the question going into November 6 is whether the stock, still 16% above where most analysts had their targets two weeks ago, needs to keep growing into its valuation or whether the Street's rapid target revisions have done enough to justify the current price.